A Year of Growth for the MCW Cancer Center
Dear Colleagues, Partners, and Friends,
On behalf of the entire MCW Cancer Center, I wish you a very happy and healthy new year.
2012 was a year of tremendous growth and change, and I want to take this opportunity to congratulate and thank MCW and the Cancer Center leadership, members, staff and partners for their hard work and commitment to our mission.
Under the leadership of Paula Traktman, PhD, Associate Director of Basic Sciences and Roy Silverstein, MD, Associate Director of Clinical Research, our research programs were evaluated and reorganized to better represent the scientific projects and strengths of our investigators. This reorganization created stronger programs with a tighter focus, and created better opportunities for collaboration.
Our membership ranks have grown to 248, and represent almost every division and department at MCW. Our recruiting efforts have resulted in 29 cancer-focused faculty joining MCW and we are in the process of recruiting other cancer researchers. We also awarded seed grant funding to MCW Cancer Center members including awards for novel ideas, young investigators, Breast/Prostate Cancer Research, Translational Research, and large project planning.
With the growth of our programs, membership and activities, and the launch of the Clinical Trials Office, we required a more robust administrative staff, and we now have over 48 full-time staff supporting the Cancer Center and Clinical Trials Office.
2012 also marked our most significant milestone to date on the path to becoming an NCI-designated Cancer Center -- a formal review by our External Scientific Advisory Board (ESAB). The ESAB is comprised of directors from NCI-Designated Centers around the country. This is an intensive, full-day review of Cancer Center research programs, clinical trials infrastructure and administration. Over 50 MCW faculty and staff helped prepare and present to the ESAB, including Dean Kershner, President Raymond, multiple Department Chairs and Center Directors, and our basic science, translational, clinical and pediatric cancer researchers throughout MCW, Children’s Hospital of Wisconsin, Froedtert Hospital, the Clement J. Zablocki VA Medical Center, and the Blood Research Institute. Their assessment and recommendations will help us become a stronger Cancer Center and provide a clearer strategy for designation.
The coming year should bring even more change and growth for the MCW Cancer Center. I look forward to continuing our important work with our outstanding team of scientists, clinicians, leaders, and administrators.
Ming You, MD, PhD
Director, MCW Cancer Center